

COVID-19 Vaccine Task Force Meeting: June 26, 2020

Proposal Considered: Variation Biotechnologies Inc. (VBI) (announced – vaccine) August 5th

Name of Members:	Nature of Interest	Action Taken
1. Mark Lievonen	None	N/A
2. Dr. Joanne Langley	J. Langley has worked with VBI on similar vaccines to those described in the VBI proposal, but holds no material interest in that proposal.** *Note: Research funds for these trials were paid to Dalhousie University. **Note: Subsequent to Task Force discussions related to VBI, the company has approached CIRN to help organize the clinical trials for its COVID vaccine.	As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary.
3. Dr. Alan Bernstein	None	N/A
4. Dr. Robert Brunham	None	N/A
5. Michel De Wilde	M. de Wilde is a board member of VBI	Deemed a conflict of interest, Michel de Wilde recused himself from deliberations and recommendations.
6. Dr. Bartha Knoppers	Did not attend meeting	N/A
7. Dr. Gary Kobinger	Did not attend meeting	N/A
8. Christopher Procyshyn	None	N/A
9. Dr. Benjamin Rovinski	None	N/A
10. Dr. Lorne Tyrrell	L. Tyrrell had supervised the PhD thesis of the current Chief Medical Officer at VBI many years ago.	As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary.
11. Dr. Sylvia van Drunen Littel-van den Hurk	None	N/A
12. Dr. André Veillette	None	N/A

COVID-19 Vaccine Task Force Meeting: July 3, 2020

Proposal Considered: Moderna (Announced August 5th) – update to CVTF on September 3rd

Name of Members:	Nature of Interest	Action Taken
1. Mark Lievonen	None	N/A
2. Dr. Joanne Langley	None	N/A
3. Dr. Alan Bernstein	None	N/A
4. Dr. Robert Brunham	None	N/A
5. Michel De Wilde	None	N/A
6. Dr. Bartha Knoppers	Did not attend meeting	N/A
7. Dr. Gary Kobinger	None	N/A
8. Christopher Procyshyn	C. Procyshyn is the co-founder and CEO of Vanrx, a company that produces biomanufacturing machinery. Prior to the creation of the task force, Moderna had purchased a Vanrx machine. The CVTF played no role in the advice on the purchase of the machine.	As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary.
9. Dr. Benjamin Rovinski	None	N/A
10. Dr. Lorne Tyrrell	None	N/A
11. Dr. Sylvia van Drunen Littel-van den Hurk	S. van den Hurk noted that VIDO-InterVac was mentioned as a collaborator for animal trials with Moderna, but that she is not involved in that work and holds no interest in it	As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary.
12. Dr. André Veillette	None	N/A

COVID-19 Vaccine Task Force Meeting: July 23, 2020

Proposal Considered: Novavax (Announced August 31st) – update provided August 20th

Name of Members:	Nature of Interest	Action Taken
1. Mark Lievonen	None	N/A
2. Dr. Joanne Langley	J. Langley noted that the university where she works has collaborated with Novavax in the past on clinical trials.	As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary.
3. Dr. Alan Bernstein	None	N/A
4. Dr. Robert Brunham	None	N/A
5. Michel De Wilde	Did not attend meetings	N/A
6. Dr. Bartha Knoppers	Did not attend meetings	N/A
7. Christopher Procyshyn	None (July 23) Did not attend meeting (August 20 th)	N/A
8. Dr. Benjamin Rovinski	None	N/A
9. Dr. Lorne Tyrrell	None	N/A
10. Dr. Sylvia van Drunen Littel-van den Hurk	None	N/A
11. Dr. André Veillette	None	N/A

COVID-19 Vaccine Task Force Meeting: July 28, 2020**Proposal Considered: Johnson & Johnson - Janssen - update on August 6th (Announced August 31st)**

Name of Members:	Nature of Interest	Action Taken
1. Mark Lievonen	None	N/A
2. Dr. Joanne Langley	J. Langley noted that the university where she works has collaborated with Janssen in the past on clinical trials.	As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary.
3. Dr. Alan Bernstein	None	N/A
4. Dr. Robert Brunham	None	N/A
5. Michel De Wilde	None	N/A
6. Dr. Bartha Knoppers	None	N/A
7. Christopher Procyshyn	None	N/A
8. Dr. Benjamin Rovinski	None	N/A
9. Dr. Lorne Tyrrell	None	N/A
10. Dr. Sylvia van Drunen Littel-van den Hurk	None	N/A
11. Dr. André Veillette	None	N/A

COVID-19 Vaccine Task Force Meeting: September 3, 2020

Proposal Considered: Sanofi / GSK (announced – Sept 22nd)

Name of Members:	Nature of Interest	Action Taken
1. Mark Lievonen	M. Lievonen was previously employed by Sanofi Pasteur (past president, retired in 2016) and holds modest shares (current value of approximately \$500). He is no longer active with the company.	Not considered a direct, material conflict but, in an abundance of caution, M. Lievonen recused himself from deliberations and recommendations.
2. Dr. Joanne Langley	J. Langley noted that the university where she works has collaborated with Sanofi Pasteur, GSK in the past on clinical trials. There is a challenge unit named after Sanofi Pasteur. She has no personal financial interests in the arrangement. *Note: Dr. Langley holds the CIHR-GSK Chair in pediatric vaccinology at Dalhousie University. The funds for this chair are held by Dalhousie University. *Note: Dr. Langley has collaborated on research projects outside of clinical trials with scientists from Sanofi (no financial compensation). *Note: Dr. Langley served as a consultant to Sanofi on influenza vaccines in 2018 (this was an ad hoc advisory board). Payment for this work was directed to academic activity in Dalhousie University's Department of Pediatrics.	As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary.
3. Dr. Alan Bernstein	None	N/A
4. Dr. Robert Brunham	None	N/A
5. Michel De Wilde	Did not attend meeting	N/A
6. Dr. Bartha Knoppers	None	N/A
7. Christopher Procyshyn	None	N/A
8. Dr. Benjamin Rovinski	B. Rovinski noted that he worked for Sanofi over 20 years ago.	Not considered a direct, material conflict but, in an abundance of caution, B. Rovinski recused himself from deliberations and recommendations.
9. Dr. Lorne Tyrrell	Did not attend meeting	N/A
10. Dr. Sylvia van Drunen Littel-van den Hurk	S. van den Hurk shared that 10 years ago, she held a small contract with Sanofi Pasteur regarding preclinical studies.	As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary.
11. Dr. André Veillette	None	N/A

